Multidisciplinary Journal of Science and Technology

CLINICAL PHARMACOLOGY OF BETA 2 ADRENOMIMETIC DRUGS

Numonova Guzaloy

Department of Pharmacology, Clinical Pharmacology and Medical Biotechnology, ASMI

Keywords: beta-2 agonists, adrenomimetics, bronchodilators, asthma, pharmacodynamics, receptor selectivity.

Abstract

Beta-2 adrenomimetic drugs, also known as beta-2 adrenergic agonists, represent one of the most important pharmacological groups used in respiratory and obstetric medicine. They act selectively on beta-2 adrenergic receptors, producing smooth muscle relaxation, bronchodilation, and inhibition of uterine contractions. These agents are crucial in the management of asthma, chronic obstructive pulmonary disease (COPD), and premature labor. However, their use requires careful consideration of pharmacokinetics, receptor selectivity, and adverse effects, particularly in patients with cardiovascular disease, diabetes, or thyroid dysfunction. This article provides an in-depth overview of the pharmacodynamics, pharmacokinetics, clinical applications, adverse reactions, and therapeutic nuances of beta-2 adrenomimetic drugs, emphasizing their role in modern clinical pharmacology and rational drug therapy.

References

1. Johnson, M. Beta2-adrenoceptors: mechanisms of action of beta2-agonists. Respiratory Medicine, 2011.

2. Cazzola, M., et al. Pharmacology and therapeutics of bronchodilators. Pharmacological Reviews, 2012.

3. Barnes, P. J. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. European Respiratory Journal, 2012.

4. Spina, D., & Page, C. P. Pharmacology of beta2-agonists in the treatment of asthma. Pharmacology & Therapeutics, 2018.

5. Pauwels, R. A., et al. Formoterol and salmeterol in chronic obstructive pulmonary disease. Lancet, 2013.